Generic Medicine Info
Hypersensitivity to amikacin and other aminoglycosides. Myasthenia gravis.
Special Precautions
Patient w/ pre-existing hearing or vestibular damage, muscular disorder (e.g. parkinsonism). Renal impairment. Premature and neonatal infants. Pregnancy and lactation. Patient Counselling May cause adverse reactions which may impair ability to drive or operate machinery. Monitoring Parameters Monitor renal function, appropriately timed peak and trough concentrations, vital signs, temperature, wt, input and output, hearing parameters.
Adverse Reactions
Neurotoxicity manifested as vestibular and permanent bilateral auditory ototoxicity, skin rash, drug fever, headache, paraesthesia, tremor, nausea and vomiting, eosinophilia, arthralgia, anaemia, hypotension, hypomagnesaemia; macular infarction following intravitreous admin.
Potentially Fatal: Nephrotoxicity, neuromuscular blockade and resp paralysis, Clostridium difficile-associated colitis.
Drug Interactions
Additive effect w/ other neurotoxic, ototoxic or nephrotoxic agents (e.g. bacitracin, cisplatin, amphotericin B, ciclosporin, tacrolimus, cefaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, and other aminoglycosides). Enhanced toxicity w/ rapidly acting diuretics (e.g. furosemide, ethacrynic acid). Increased creatinine serum level w/ cephalosporins. Indomethacin may increase the plasma concentration of amikacin in neonates. Increased risk of hypocalcaemia w/ biphosphonates. Increased risk of nephrotoxicity and possibly ototoxicity w/ platinum compounds. Increased risk of neuromuscular blockade and consequent resp depression w/ anaesth or muscle relaxants (e.g. ether, halothane, d-tubocurarine, succinylcholine decamethonium, atracurium, rocuronium, vecuronium).
CIMS Class
ATC Classification
S01AA21 - amikacin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
J01GB06 - amikacin ; Belongs to the class of other aminoglycosides. Used in the systemic treatment of infections.
D06AX12 - amikacin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.
Disclaimer: This information is independently developed by CIMS based on amikacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in